HOOKIPA’s Gilead Sciences Collaboration for HIV and HBV Therapeutic Vaccines Advancing Towards Clinical EntryGlobeNewsWire • 01/06/20
HOOKIPA Announces First Patient Dosed in Phase 1/2 Clinical Trial for HB-201 for the Treatment of Human Papillomavirus 16-Positive CancersGlobeNewsWire • 12/30/19
Hookipa's Technology Appears To Be A Vaccine Gamechanger Against Infectious Disease And CancerSeeking Alpha • 11/20/19
HOOKIPA to Present Data Demonstrating the Potential of its TheraT® Technology at the Upcoming CICON Conference in ParisGlobeNewsWire • 09/19/19
Hookipa Gains FDA Signal To Begin HPV-Cancer Drug; Allows For Catalyst In Late 2020Seeking Alpha • 07/31/19